HIF-1 and HIF-2 function as critical transcriptional activators that respond to low-oxygen (hypoxic) environments by modulating dozens of pathways crucial for tumor adaptation and progression. They drive angiogenesis—the formation of new blood vessels—to supply rapidly growing tumors with oxygen and nutrients, enhance tumor cell invasiveness, and subvert immune cell infiltration and function within the tumor microenvironment. The overexpression of these factors often portends poor prognosis and resistance to conventional therapies, highlighting the urgent need to develop therapeutics targeting these pathways.

Previously, selective inhibitors of HIF-2, such as belzutifan, have achieved clinical approval for cancers like advanced renal cell carcinoma. However, exclusive targeting of HIF-2 overlooks the complementary and distinct roles played by HIF-1 in cancer biology. This has propelled efforts to develop inhibitors with dual specificity, enabling a more comprehensive disruption of HIF-driven oncogenic processes. Researchers hypothesized that dual HIF-1/2 inhibition could overcome limitations of monotherapies and enhance therapeutic outcomes across a spectrum of tumor types.

At the heart of this drug discovery effort is an advanced computational drug design technology called Site-Identification by Ligand Competitive Saturation (SILCS). This method meticulously maps ligand-binding hotspots across protein surfaces based on structural data, enabling precise prediction of small molecules capable of binding target sites with high affinity. Using the known crystal structure of HIF-2, the team identified three conserved pockets shared between HIF-1 and HIF-2, thereby unlocking the potential for designing inhibitors active against both isoforms.

The researchers generated a focused library of candidate compounds predicted by SILCS to bind these conserved domains and subjected them to rigorous biochemical assays. Several molecules demonstrated robust binding to both HIF-1 and HIF-2, inducing proteasomal degradation of the transcription factors and effectively silencing downstream gene activation. These dual HIF inhibitors exhibited potent activity across multiple cancer cell lines in vitro, reducing expression of genes involved in angiogenesis, metabolism, and immune evasion.

Moving to in vivo models, the new drugs significantly impeded tumor growth in mouse models of breast, colorectal, melanoma, and prostate cancers. The inhibitors curtailed angiogenesis within tumors, diminishing blood vessel formation and thus nutrient supply, as well as reducing their propensity to invade adjacent tissue. Importantly, the treatment was well tolerated and administered orally, emphasizing clinical translatability.

Even more striking were the results when the dual inhibitors were administered alongside immune checkpoint blockade therapies such as anti-CTLA-4 or anti-PD1 antibodies. This combinatorial approach led to complete tumor remission in over half the treated animals, including those bearing tumors that were resistant to checkpoint inhibitors alone. Remarkably, these mice remained tumor-free long term and resisted rechallenge with fresh cancer cells, indicating a durable and systemic anti-tumor immune response had been established.

Detailed immunoprofiling revealed that dual HIF-1/2 inhibition reshaped the tumor immune microenvironment by reducing immunosuppressive cell populations, including myeloid-derived suppressor cells and regulatory T cells. Concurrently, there was an increase in cytotoxic T lymphocytes and natural killer (NK) cells, which are pivotal for cancer cell eradication, particularly when combined with checkpoint immunotherapy. This synergistic mechanism may explain the substantial efficacy of the combination regimen.

The discovery of these dual HIF inhibitors marks a significant conceptual advance, highlighting the therapeutic value of targeting conserved domains shared by paralog transcription factors involved in cancer progression. The translational potential is heightened by the oral bioavailability and tolerability observed in preclinical models. This approach could address unmet clinical needs related to hypoxic tumors, which are often refractory to conventional and immune-based therapies.

According to Gregg L. Semenza, a leading expert and co-senior author of the study, “The dual inhibition of HIF-1 and HIF-2 represents an exciting strategy for overcoming tumor hypoxia-induced resistance mechanisms, with the possibility to greatly expand the therapeutic landscape across multiple malignancies.” The fusion of computational design and experimental validation adopted in this study underscores the power of interdisciplinary efforts in accelerating drug development.

As cancer remains a multifaceted and heterogeneous disease, interventions that simultaneously disrupt multiple oncogenic pathways hold promise for improved patient outcomes. The dual HIF inhibitors exemplify such polypharmacology, capable of targeting the dynamic interplay between tumor metabolism, angiogenesis, and immune suppression. Future clinical trials will be essential to confirm efficacy and safety in humans, paving the way for a potentially paradigm-shifting class of anti-cancer therapeutics.

This innovative work also sets the stage for further exploration into combinatorial drug design targeting transcription factor families, which have traditionally been considered challenging constituents of the “undruggable” genome. The insights gleaned from targeting HIF-1/2 may inform strategies against other transcriptional regulators implicated in diverse diseases beyond oncology, expanding the horizons of precision medicine.

In summary, the development of small-molecule dual inhibitors against HIF-1 and HIF-2 transcription factors represents a transformative advance in cancer therapy. By leveraging state-of-the-art computational and experimental techniques, researchers have achieved comprehensive disruption of tumor adaptive pathways, demonstrating significant tumor regression and synergy with immunotherapy. These findings offer compelling hope for overcoming the longstanding clinical challenge posed by tumor hypoxia and advancing more effective, durable cancer treatments.

Subject of Research: Animals
Article Title: Targeting conserved domains of hypoxia-inducible factors for cancer therapy
News Publication Date: 2-Apr-2026
Web References: https://rupress.org/jem
References: Salman et al., Journal of Experimental Medicine, DOI: 10.1084/jem.20251009
Image Credits: © 2026 Salman et al., Originally published in Journal of Experimental Medicine
Keywords: Cancer, Breast cancer, Colorectal cancer, Skin cancer, Melanoma, Prostate cancer, Immunotherapy

Pazopanib’s triad of actions — inhibition of vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-KIT — disrupts the angiogenic pathways crucial for tumor survival. Tumors rely heavily on angiogenesis, the formation of new blood vessels, to sustain rapid growth and metastasis. By targeting these pathways, pazopanib effectively starves tumors, preventing nutrient delivery and impeding their ability to expand. This mechanism, when integrated with conventional chemotherapy and radiotherapy protocols, could potentially amplify therapeutic efficacy by weakening tumors’ defenses and sensitizing them to cytotoxic agents and radiation damage.

A recent observational study conducted at the Warsaw Mother and Child Institute involved a small cohort of eleven pediatric patients aged 5 to 17 years, all diagnosed with primary multi-metastatic Ewing sarcoma. These patients received pazopanib in conjunction with standard first-line treatments, including chemotherapy, radiotherapy, and, in some cases, surgical intervention or stem cell transplantation. Treatment with pazopanib was carefully monitored over an average period of 1.7 years. This regimen was strategically paused during surgical procedures and halted should disease progression or unacceptable toxicity emerge. The study emphasized rigorous imaging and laboratory evaluations to assess tumor response and closely track adverse effects.

Remarkably, the addition of pazopanib demonstrated a significant impact on clinical outcomes. Approximately 85.7% of patients survived two years post-diagnosis, a stark improvement compared to historical survival benchmarks in this patient population. Furthermore, nearly 68.2% experienced no disease progression at two years, indicating substantial stabilization or regression of their malignancies. Though one patient succumbed to the disease, and others experienced relapse or progression, the majority exhibited positive responses— a valuable beacon of hope for clinicians and families grappling with this devastating diagnosis.

The tolerability profile of pazopanib in these pediatric patients was notably favorable. Despite concerns about the cumulative toxicity when combining multiple cancer treatments, pazopanib’s side effects were minimal and manageable, allowing patients to maintain a reasonable quality of life. Importantly, after completion of intravenous treatments, patients were able to continue pazopanib therapy orally at home, reducing hospital visits and enabling a semblance of normalcy for these children during arduous treatment periods. This oral administration potentially offers a practical advantage in long-term management of multi-metastatic disease.

From a mechanistic perspective, pazopanib’s role in hindering angiogenesis is particularly crucial in Ewing sarcoma, which is characterized by aggressive vascular invasion and rapid metastatic dissemination. By impairing these blood vessel networks, the drug targets the tumor microenvironment—a growing focus of cancer therapeutics aimed at disrupting the supportive niche tumors require for expansion. Additionally, when administered early in the treatment course, pazopanib might augment the susceptibility of tumor cells to chemotherapy and radiation by depriving them of angiogenic protection mechanisms.

The implications of this research are profound, yet the authors prudently caution against premature changes to standard care protocols pending validation through larger, multicentric randomized clinical trials. Multi-metastatic Ewing sarcoma’s rarity poses challenges for recruitment and statistical power in such expansive studies, but collaborative international efforts could overcome these hurdles. The promising early outcomes documented at the Warsaw Mother and Child Institute set a compelling precedent to explore pazopanib’s benefits further and might inspire novel clinical trial designs integrating targeted therapies into pediatric oncology.

Beyond survival metrics, the study highlights an encouraging qualitative dimension: the remarkably good quality of life maintained by patients during combined treatment phases. Cancer therapy in children often involves balancing efficacy against the risk of debilitating side effects and long-lasting toxicities. Pazopanib’s manageable safety profile and the possibility of transitioning to outpatient oral therapy align well with the goal of minimizing treatment burden, preserving patient well-being, and supporting developmental needs.

This investigational approach—combining targeted therapy with traditional oncological modalities—reflects the broader oncological paradigm shift toward precision medicine. Instead of solely relying on non-specific cytotoxic treatments, integrating molecularly targeted agents like pazopanib addresses cancer’s multifaceted biology, potentially enhancing outcomes and reducing attrition through drug resistance. Pediatric oncology, historically slower to adopt such strategies due to drug approval complexities and safety concerns, now stands at the cusp of significant therapeutic evolution driven by such pioneering studies.

It remains to be seen whether pazopanib’s efficacy observed in children will extend to other malignancies characterized by robust angiogenesis and metastasis or if combination regimens can be optimized to maximize synergistic effects. Ongoing pharmacodynamic studies to elucidate the ideal dosing, timing, and combination partners for pazopanib will be essential to consolidate its role within multi-modality treatment frameworks. Furthermore, biomarker research may enable selection of patients most likely to respond, enhancing personalized treatment approaches and avoiding unnecessary exposure among non-responders.

The hope expressed by Prof Anna Raciborska and her colleagues, who led this groundbreaking observational study, is that future funding and international partnerships, perhaps facilitated by European Union programs, will catalyze extensive clinical trials. Such efforts are crucial to move from promising preliminary data to evidence-based standard practice changes that can transform the prognosis of children suffering with multi-metastatic Ewing sarcoma globally.

Ultimately, these findings inject renewed hope into an area of pediatric oncology that has experienced limited progress for decades. Pazopanib’s potential to extend survival with manageable toxicity represents a pivotal step forward, underscoring the importance of continuing to explore, validate, and expand the therapeutic arsenal against this life-threatening disease. It is an urgent call to the scientific community to harness targeted therapies in concert with conventional treatments, advancing toward the long-sought goal of turning multi-metastatic Ewing sarcoma from a deadly diagnosis into a manageable condition.

Subject of Research: People
Article Title: PAZOPANIB IN PATIENTS WITH PRIMARY MULTI-METASTATIC BONE
News Publication Date: 23-Oct-2025
Web References: 10.3389/fonc.2025.1653015
References: Article published in Frontiers in Oncology
Keywords: Ewing sarcoma, multi-metastatic bone cancer, pediatric oncology, pazopanib, targeted therapy, angiogenesis inhibition, survival rate, chemotherapy, radiotherapy, quality of life, observational study, cancer treatment innovation